Imatinib (Gleevec, Novartis), an inhibitor of BCR-ABL, platelet-derived growth factor, and KIT receptor tyrosine kinases, is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. We describe a case of activation of chronic hepatitis B infection associated with imatinib therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716906 | PMC |
| http://dx.doi.org/10.1007/s12072-008-9099-5 | DOI Listing |
Publication Analysis
Top Keywords
chronic hepatitis
8
hepatitis infection
8
reactivation chronic
4
infection imatinib
4
imatinib mesylate
4
mesylate therapy
4
therapy imatinib
4
imatinib gleevec
4
gleevec novartis
4
novartis inhibitor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!